SCHEMBL20140277

SCHEMBL20140277

N#Cc1nn(Cc2cncnc2)c2ncccc12

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ELANE P08246 9/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP11B1 P15538 1/20 0.36
APP P05067 3/20 0.36
SNCA P37840 3/20 0.36
RET P07949 1/20 0.36
PDE9A O76083 2/20 0.33
LMNA P02545 2/20 0.33
MAPK1 P28482 2/20 0.33
HTT P42858 2/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20139756 0.86 L3MBTL1 (0.51) ELANEL3MBTL1APPSNCAPDE9A
SCHEMBL20140783 0.85 L3MBTL1 (0.63) ELANEL3MBTL1APPSNCALMNA
SCHEMBL20140776 0.84 ELANE (0.42) ELANEL3MBTL1
SCHEMBL20140374 0.82 L3MBTL1 (0.49) ELANEL3MBTL1APPSNCARET
SCHEMBL20140434 0.82 L3MBTL1 (0.46) ELANEL3MBTL1APPSNCARET
SCHEMBL20140381 0.82 ELANE (0.56) ELANEL3MBTL1APPSNCARET
SCHEMBL20140433 0.80 L3MBTL1 (0.49) L3MBTL1LMNAMAPK1HTTPTGDR2
SCHEMBL28253344 0.80 ELANE (0.43) ELANEAPPSNCALMNAMAPK1
SCHEMBL20161099 0.80 L3MBTL1 (0.72) L3MBTL1LMNAMAPK1HTTPTGDR2
SCHEMBL9925005 0.79 L3MBTL1 (0.49) ELANEL3MBTL1LMNAMAPK1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
EP-3538520-A2 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-09-18 EP disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A ELANE 2411/4885L3MBTL1 4698/4885CYP11B1 166/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A ELANE 2419/4885L3MBTL1 4695/4885CYP11B1 175/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A ELANE 2419/4885L3MBTL1 4695/4885CYP11B1 175/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A ELANE 2411/4885L3MBTL1 4698/4885CYP11B1 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.